The company's initial target is immuno-oncology projects but there are plans to expand into autoimmune disease, infectious disease, and more.

Experts hail the ‘very exciting” discovery that the oft-observed protection against triple-negative breast cancer afforded by breastfeeding may be due to resident T cells left behind in the breast.

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

We included 77 studies: 47 studies reported factors from clinicians' perspective, 33 studies reported patients' perspective, 23 studies reported implementation strategies, and seven studies evaluated ...

Ipsen is acquiring next-gen immuno-oncology biotech ImCheck Therapeutics for its investigational cancer combination therapy in a deal worth up to 1 billion euros (about $1.16 billion). The French ...

Bridging the Gap: The Evolving Landscape of CNS Management in Small Cell Lung Cancer: Prophylactic Cranial Irradiation in the Modern Era The following represents disclosure information provided by the ...

The new venture is backed by Biovance Capital, Torrey Pines Investment, and OrbiMed. Mondego Bio is advancing a portfolio of first- and best-in-class PTPN2 inhibitors designed to transform cancer ...